All Stories

  1. Impact of fludarabine dose on outcome after allo-HSCT with reduced intensity conditioning for older patients with AML

    Article • British Journal of Pharmacology, June 2025, Springer Science + Business Media

    Professor Eric DECONINCK

  2. Directionality of HLA-DP permissive mismatches improves risk prediction in HCT for acute leukemia and MDS

    Article • Blood, October 2024, American Society of Hematology

    Professor Eric DECONINCK

  3. Kidney Transplantation After Allogeneic Hematopoietic Cell Transplantation

    Article • Kidney International Reports, April 2024, Elsevier

    Professor Eric DECONINCK

  4. Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP‐EBMT study

    Article • European Journal Of Haematology, April 2023, Wiley

    Professor Eric DECONINCK

  5. Conventional Therapeutics in BPDCN Patients—Do They Still Have a Place in the Era of Targeted Therapies?

    Article • Cancers, August 2022, MDPI AG

    Professor Eric DECONINCK

  6. An inherited gain‐of‐function risk allele in EPOR predisposes to familial JAK2 V617F my...

    Article • British Journal of Haematology, March 2022, Wiley

    Professor Eric DECONINCK

  7. Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party

    Article • British Journal of Pharmacology, November 2021, Springer Science + Business Media

    Professor Eric DECONINCK

  8. Vaccination coverage in hematological patients undergoing chemotherapy: Should we move towards personalized vaccination?

    Article • Vaccine, November 2021, Elsevier

    Professor Eric DECONINCK

  9. Lymphoblastic T Cells and Mature NK Cells With the Same TCRγ Rearrangement: A Common Origin?

    Article • HemaSphere, August 2021, Wiley

    Professor Eric DECONINCK

  10. Investigating the impact of posaconazole prophylaxis on systematic fungal screening using galactomannan antigen, Aspergillus fumigatus qPCR, and Mucorales qPCR

    Article • Journal de Mycologie Médicale, June 2021, Elsevier

    Professor Eric DECONINCK

  11. Oral therapy adherence and satisfaction in patients with multiple myeloma

    Article • Annals of Hematology, May 2021, Springer Science + Business Media

    Professor Eric DECONINCK

  12. Second allogeneic haematopoietic cell transplantation using HLA‐matched unrelated versus T‐cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia

    Article • British Journal of Haematology, April 2021, Wiley

    Professor Eric DECONINCK

  13. Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis

    Article • Blood Advances, March 2021, American Society of Hematology

    Dr Philippe SAAS, Professor Eric DECONINCK

  14. Oncogenetic landscape of lymphomagenesis in coeliac disease

    Article • Gut, February 2021, BMJ

    Professor Eric DECONINCK

  15. Impact of early candidemia on the long-term outcome of allogeneic hematopoietic stem cell transplant in non-leukemic patients: an outcome analysis on behalf of IDWP–EBMT

    Article • British Journal of Pharmacology, January 2021, Springer Science + Business Media

    Professor Eric DECONINCK

  16. Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial

    Article • Leukemia, January 2021, Springer Science + Business Media

    Professor Eric DECONINCK

  17. A case report of blastic plasmacytoid dendritic cell neoplasm in a hispanic child

    Article • Leukemia Research Reports, January 2021, Elsevier

    Professor Eric DECONINCK

  18. Optimizing selection of double cord blood units for transplantation of adult patients with malignant diseases

    Article • Blood Advances, December 2020, American Society of Hematology

    Professor Eric DECONINCK

  19. Scoring system for clinically significant CMV infection in seropositive recipients following allogenic hematopoietic cell transplant: an SFGM-TC study

    Article • British Journal of Pharmacology, December 2020, Springer Science + Business Media

    Professor Eric DECONINCK

  20. Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics

    Article • Frontiers in Oncology, December 2020, Frontiers

    Professor Eric DECONINCK

  21. Pyogenic Granuloma During Ibrutinib Therapy for B-Cell Neoplasia

    Article • JCO Oncology Practice, December 2020, American Society of Clinical Oncology (ASCO)

    Professor Eric DECONINCK

  22. Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT

    Article • British Journal of Pharmacology, November 2020, Springer Science + Business Media

    Professor Eric DECONINCK

  23. Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: A French nationwide study

    Article • American Journal of Hematology, November 2020, Wiley

    Professor Eric DECONINCK

  24. Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide

    Article • Acta Oncologica, October 2020, Acta Dermato-Venereologica

    Professor Eric DECONINCK

  25. Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape

    Article • Haematologica, October 2020, Ferrata Storti Foundation (Haematologica)

    Dr Philippe SAAS, Professor Eric DECONINCK

  26. Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party—EBMT

    Article • British Journal of Pharmacology, October 2020, Springer Science + Business Media

    Professor Eric DECONINCK

  27. Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party

    Article • British Journal of Pharmacology, October 2020, Springer Science + Business Media

    Professor Eric DECONINCK

  28. Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study

    Article • Leukemia, September 2020, Springer Science + Business Media

    Professor Eric DECONINCK

  29. Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia

    Article • Leukemia, September 2020, Springer Science + Business Media

    Professor Eric DECONINCK

  30. Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the A...

    Article • British Journal of Pharmacology, September 2020, Springer Science + Business Media

    Professor Eric DECONINCK

  31. Platelet transfusions in haematologic malignancies in the last six months of life

    Article • Vox Sanguinis, August 2020, Wiley

    Professor Eric DECONINCK

  32. Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy

    Article • Journal of Clinical Oncology, August 2020, American Society of Clinical Oncology (ASCO)

    Professor Eric DECONINCK

  33. Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood...

    Article • American Journal of Hematology, July 2020, Wiley

    Professor Eric DECONINCK

  34. Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors

    Article • Journal of Hematology & Oncology, July 2020, Springer Science + Business Media

    Professor Eric DECONINCK

  35. Impact of detectable measurable residual disease on umbilical cord blood transplantation

    Article • American Journal of Hematology, June 2020, Wiley

    Professor Eric DECONINCK

  36. Antiplatelet Antibodies Do Not Predict the Response to Intravenous Immunoglobulins during Immune Thrombocytopenia

    Article • Journal of Clinical Medicine, June 2020, MDPI AG

    Professor Eric DECONINCK

  37. Blastic Plasmacytoid Dendritic Cell Neoplasm

    Article • Hematology/Oncology Clinics of North America, June 2020, Elsevier

    Professor Eric DECONINCK

  38. Blastic Plasmacytoid Dendritic Cell Neoplasm

    Article • Hematology/Oncology Clinics of North America, June 2020, Elsevier

    Professor Eric DECONINCK

  39. Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma

    Article • British Journal of Pharmacology, May 2020, Springer Science + Business Media

    Professor Eric DECONINCK

  40. CD34 + cell dose effects on clinical outcomes after T‐cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working Party...

    Article • American Journal of Hematology, May 2020, Wiley

    Professor Eric DECONINCK

  41. Arsenic Trioxide Treatment during Pregnancy for Acute Promyelocytic Leukemia in a 22-Year-Old Woman

    Article • Case Reports in Hematology, March 2020, Wiley

    Professor Eric DECONINCK

  42. CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm

    Article • Leukemia, February 2020, Springer Science + Business Media

    Dr Philippe SAAS, Professor Eric DECONINCK

  43. Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study

    Article • The Lancet Haematology, January 2020, Elsevier

    Professor Eric DECONINCK

  44. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?

    Article • Blood Advances, December 2019, American Society of Hematology

    Dr Philippe SAAS, Professor Eric DECONINCK

  45. Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT

    Article • Blood Cancer Journal, November 2019, Springer Science + Business Media

    Professor Eric DECONINCK

  46. The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation

    Article • Leukemia, November 2019, Springer Science + Business Media

    Professor Eric DECONINCK

  47. Altered thymic CD4+ T-cell recovery after allogeneic hematopoietic stem cell transplantation is critical for nocardiosis

    Article • Current Research in Translational Medicine, November 2019, Elsevier

    Dr Philippe SAAS, Professor Eric DECONINCK

  48. Correction of Severe Myelofibrosis, Impaired Platelet Functions and Abnormalities in a Patient with Gray Platelet Syndrome Successfully Treated by Stem Cell Transplantation

    Article • Platelets, September 2019, Taylor & Francis

    Professor Eric DECONINCK

  49. Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT

    Article • British Journal of Pharmacology, July 2019, Springer Science + Business Media

    Professor Eric DECONINCK

  50. Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT

    Article • British Journal of Pharmacology, May 2019, Springer Science + Business Media

    Professor Eric DECONINCK

  51. Cytomegalovirus Infection Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation from a Single Institution

    Article • Biology of Blood and Marrow Transplantation, March 2019, Elsevier

    Professor Eric DECONINCK

  52. CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor–Engineered T Cells

    Article • Cancer Research, February 2019, American Association for Cancer Research (AACR)

    Professor Eric DECONINCK

  53. EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL)

    Article • British Journal of Pharmacology, January 2019, Springer Science + Business Media

    Professor Eric DECONINCK

  54. Clinical and biological features in PIEZO1-hereditary xerocytosis and Gardos channelopathy: a retrospective series of 126 patients

    Article • Haematologica, January 2019, Ferrata Storti Foundation (Haematologica)

    Professor Eric DECONINCK

  55. Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission

    Article • American Journal of Hematology, December 2018, Wiley

    Professor Eric DECONINCK

  56. NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study

    Article • Gut, November 2018, BMJ

    Professor Eric DECONINCK

  57. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, September 2018, New England Journal of Medicine (NEJM/MMS)

    Professor Eric DECONINCK

  58. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party E

    Article • American Journal of Hematology, August 2018, Wiley

    Professor Eric DECONINCK

  59. Cord Blood Unit Dominance Analysis and Effect of the Winning Unit on Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee of Cellular Therap...

    Article • Biology of Blood and Marrow Transplantation, August 2018, Elsevier

    Professor Eric DECONINCK

  60. Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group

    Article • Haematologica, July 2018, Ferrata Storti Foundation (Haematologica)

    Professor Eric DECONINCK

  61. Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute L...

    Article • Haematologica, May 2018, Ferrata Storti Foundation (Haematologica)

    Professor Eric DECONINCK

  62. Development of a quantitative PCR detecting Cunninghamella bertholletiae to help in diagnosing this rare and aggressive mucormycosis

    Article • British Journal of Pharmacology, April 2018, Springer Science + Business Media

    Steffi Rocchi, Professor Eric DECONINCK

  63. Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases

    Article • JAMA Oncology, April 2018, American Medical Association (AMA)

    Professor Eric DECONINCK

  64. Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation

    Article • Biology of Blood and Marrow Transplantation, April 2018, Elsevier

    Professor Eric DECONINCK

  65. Factors related to the outcome of prophylactic platelet transfusions in patients with hematologic malignancies: an observational study

    Article • Transfusion, March 2018, Wiley

    Professor Eric DECONINCK

  66. Incidence, Risk Factors, and Long-term Outcome of Acute Leukemia Patients With Early Candidemia After Allogeneic Stem Cell Transplantation: A Study by the Acute Leukemia and Infectious Diseases Working Parties of European Society for Blood and Marrow T...

    Article • Clinical Infectious Diseases, February 2018, Oxford University Press (OUP)

    Professor Eric DECONINCK

  67. Nationwide survey on the use of horse antithymocyte globulins (ATGAM) in patients with acquired aplastic anemia: A report on behalf of the French Reference Center for Aplastic Anemia

    Article • American Journal of Hematology, February 2018, Wiley

    Professor Eric DECONINCK

  68. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma

    Article • Blood, January 2018, American Society of Hematology

    Professor Eric DECONINCK

  69. A new approach for diagnosing chronic myelomonocytic leukemia using structural parameters of Sysmex XNTM analyzers in routine laboratory practice

    Article • Scandinavian Journal of Clinical and Laboratory Investigation, January 2018, Taylor & Francis

    Professor Eric DECONINCK

  70. Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie Cell...

    Article • American Journal of Hematology, January 2018, Wiley

    Professor Eric DECONINCK

  71. Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia

    Article • Journal of Internal Medicine, January 2018, Wiley

    Professor Eric DECONINCK

  72. Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission

    Article • Oncotarget, December 2017, Impact Journals, LLC

    Professor Eric DECONINCK

  73. Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy

    Article • JAMA, December 2017, American Medical Association (AMA)

    Professor Eric DECONINCK

  74. More on Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, November 2017, New England Journal of Medicine (NEJM/MMS)

    Professor Eric DECONINCK

  75. Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, September 2017, New England Journal of Medicine (NEJM/MMS)

    Professor Eric DECONINCK

  76. Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie ...

    Article • Annals of Oncology, September 2017, Elsevier

    Professor Eric DECONINCK

  77. Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm

    Article • Haematologica, August 2017, Ferrata Storti Foundation (Haematologica)

    Dr Philippe SAAS, Professor Eric DECONINCK

  78. Centre characteristics and procedure‐related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT)

    Article • British Journal of Haematology, June 2017, Wiley

    Professor Eric DECONINCK

  79. Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT

    Article • American Journal of Hematology, May 2017, Wiley

    Professor Eric DECONINCK

  80. Paecilomyces variotii Fungemia in a Patient with Lymphoma Needing Liver Transplant

    Article • Mycopathologia, April 2017, Springer Science + Business Media

    Professor Eric DECONINCK

  81. Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA

    Article • Leukemia Research, March 2017, Elsevier

    Professor Eric DECONINCK

  82. Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1

    Article • Blood Advances, February 2017, American Society of Hematology

    Professor Eric DECONINCK

  83. Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working p...

    Article • American Journal of Hematology, February 2017, Wiley

    Professor Eric DECONINCK

  84. DNA damage response defect in Williams-Beuren syndrome

    Article • International Journal of Molecular Medicine, January 2017, Spandidos Publications

    Professor Eric DECONINCK

  85. Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation

    Article • British Journal of Pharmacology, December 2016, Springer Science + Business Media

    Professor Eric DECONINCK

  86. French Intensive Care Society, International congress – Réanimation 2016

    Article • Annals of Intensive Care, June 2016, Springer Science + Business Media

    Professor Mabrouk Bahloul, MD, PhD Pierre-Louis Tharaux, Professor Eric DECONINCK

  87. Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT

    Article • Haematologica, May 2016, Ferrata Storti Foundation (Haematologica)

    Professor Eric DECONINCK

  88. Exposure to hypomethylating agent, 5-azacytidine, may improve iCasp9 suicide gene therapy for treating GvHD in allografts

    Article • Gene Therapy, May 2016, Springer Science + Business Media

    Professor Eric DECONINCK

  89. Long-term follow-up of 90Y-ibritumomab-tiuxetan (90YIT) in the conditioning of autologous hematopoietic transplantation for indolent and mantle cell lymphomas in a single French center

    Article • British Journal of Pharmacology, April 2016, Springer Science + Business Media

    Professor Eric DECONINCK

  90. Erratum to: New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies

    Article • Experimental Hematology and Oncology, December 2015, Springer Science + Business Media

    Dr Philippe SAAS, Professor Eric DECONINCK

  91. New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies

    Article • Experimental Hematology and Oncology, December 2015, Springer Science + Business Media

    Dr Philippe SAAS, Professor Eric DECONINCK

  92. Is shared decision-making vanishing at the end-of-life? A descriptive and qualitative study of advanced cancer patients’ involvement in specific therapies decision-making

    Article • BMC Palliative Care, November 2015, Springer Science + Business Media

    Professor Eric DECONINCK

  93. Severe chronic primary neutropenia in adults: report on a series of 108 patients

    Article • Blood, October 2015, American Society of Hematology

    Professor Eric DECONINCK

  94. Allogeneic stem cell transplantation (allo-SCT) for de novo Ph+ AML: a study from the French Society of Bone Marrow Transplantation and Cell Therapy

    Article • British Journal of Pharmacology, September 2015, Springer Science + Business Media

    Professor Eric DECONINCK

  95. A Phase 2 study of L‐asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL‐SA2‐2008 study

    Article • American Journal of Hematology, August 2015, Wiley

    Professor Eric DECONINCK

  96. Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party...

    Article • Biology of Blood and Marrow Transplantation, August 2015, Elsevier

    Professor Eric DECONINCK

  97. Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Retrospective Study of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

    Article • Biology of Blood and Marrow Transplantation, August 2015, Elsevier

    Professor Eric DECONINCK

  98. CombiningAspergillusmitochondrial and ribosomal QPCR, in addition to galactomannan assay, for early diagnosis of invasive aspergillosis in hematology patients

    Article • Medical Mycology, July 2015, Oxford University Press (OUP)

    Professor Eric DECONINCK

  99. Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French‐Belgian‐Swiss APL group

    Article • Cancer, April 2015, Wiley

    Professor Eric DECONINCK

  100. La mucite post-allogreffe de cellules souches hématopoïétiques : facteurs de risque, conséquences cliniques et prévention

    Article • Pathologie Biologie, April 2015, Elsevier

    Professor Eric DECONINCK

  101. Fatal Thrombotic Thrombocytopenic Purpura in a Psoriasis Patient Treated with Ustekinumab and Methotrexate

    Article • Acta Dermato-Venereologica, January 2015, Acta Dermato-Venereologica

    Professor Eric DECONINCK

  102. Reduced‐intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the Europea...

    Article • Cancer, November 2014, Wiley

    Professor Eric DECONINCK

  103. In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent

    Article • Haematologica, November 2014, Ferrata Storti Foundation (Haematologica)

    Dr Philippe SAAS, Professor Eric DECONINCK

  104. Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis

    Article • Biology of Blood and Marrow Transplantation, November 2014, Elsevier

    Professor Eric DECONINCK

  105. Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto‐SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM‐TC

    Article • European Journal Of Haematology, October 2014, Wiley

    Professor Eric DECONINCK

  106. Allogeneic hematopoietic stem cell transplantation for T‐prolymphocytic leukemia: a report from the French society for stem cell transplantation (SFGM‐TC)

    Article • European Journal Of Haematology, September 2014, Wiley

    Professor Eric DECONINCK

  107. Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients

    Article • Leukemia, August 2014, Springer Science + Business Media

    Professor Eric DECONINCK

  108. Increased Incidence and Characteristics of Alveolar Echinococcosis in Patients With Immunosuppression-Associated Conditions

    Article • Clinical Infectious Diseases, July 2014, Oxford University Press (OUP)

    Professor Eric DECONINCK

  109. Posaconazole prophylaxis in neutropenic patients with hematological malignancies: limits in clinical practice

    Article • Medical Mycology, July 2014, Oxford University Press (OUP)

    Professor Eric DECONINCK

  110. Diagnosis and management of nocardiosis after bone marrow stem cell transplantation in adults: Lack of lymphocyte recovery as a major contributing factor

    Article • Pathologie Biologie, June 2014, Elsevier

    Dr Philippe SAAS, Professor Eric DECONINCK

  111. A 10-year survey of fungal aerocontamination in hospital corridors: a reliable sentinel to predict fungal exposure risk?

    Article • Journal of Hospital Infection, May 2014, Elsevier

    Professor Eric DECONINCK

  112. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial

    Article • Leukemia, April 2014, Springer Science + Business Media

    Professor Eric DECONINCK

  113. Evaluation of invasive aspergillosis risk of immunocompromised patients alternatively hospitalized in hematology intensive care unit and at home

    Article • Indoor Air, April 2014, Wiley

    Steffi Rocchi, Professor Eric DECONINCK

  114. Azole-Resistant Aspergillus fumigatus Isolate with the TR34/L98H Mutation in Both a Fungicide-Sprayed Field and the Lung of a Hematopoietic Stem Cell Transplant Recipient with Invasive Aspergillosis

    Article • Journal of Clinical Microbiology, February 2014, ASM Journals

    Steffi Rocchi, Professor Eric DECONINCK

  115. Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin's lymphoma

    Article • Journal of Clinical Pharmacy and Therapeutics, January 2014, Hindawi Publishing Corporation

    Professor Eric DECONINCK

  116. Opposing Mcl-1, the GALIG proapoptotic gene is upregulated as neutrophils die and underexpressed in Acute Myeloid Leukemia cells

    Article • Molecular Immunology, November 2013, Elsevier

    Professor Eric DECONINCK

  117. Double umbilical cord blood transplantation for hematological malignancies: A long-term analysis from the SFGM-TC registry

    Article • Experimental Hematology, November 2013, Elsevier

    Professor Eric DECONINCK

  118. E-santé et organisation des soins : structuration de la thérapeutique anti-cancéreuse en Franche-Comté

    Article • European Research in Telemedicine / La Recherche Européenne en Télémédecine, November 2013, Elsevier

    Professor Eric DECONINCK

  119. Cost-effectiveness and clinical outcomes of double versus single cord blood transplantation in adults with acute leukemia in France

    Article • Haematologica, October 2013, Ferrata Storti Foundation (Haematologica)

    Professor Eric DECONINCK

  120. Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group

    Article • Haematologica, August 2013, Ferrata Storti Foundation (Haematologica)

    Professor Eric DECONINCK

  121. Conduite à tenir devant une réactivation ou une infection à virus respiratoire syncytial, herpèsvirus 6 et adénovirus après allogreffe de cellules souches hématopoïétiques

    Article • Pathologie Biologie, August 2013, Elsevier

    Professor Eric DECONINCK

  122. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Dyskeratosis Congenita

    Article • Biology of Blood and Marrow Transplantation, August 2013, Elsevier

    Professor Eric DECONINCK

  123. Long‐term follow‐up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients

    Article • American Journal of Hematology, June 2013, Wiley

    Professor Eric DECONINCK

  124. Unrelated Cord Blood Transplantation

    Article • Transplantation, May 2013, Wolters Kluwer Health

    Professor Eric DECONINCK

  125. Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire

    Article • European Journal Of Haematology, March 2013, Wiley

    Professor Eric DECONINCK

  126. A successful renal transplantation for renal failure after dasatinib-induced thrombotic thrombocytopenic purpura in a patient with imatinib-resistant chronic myelogenous leukaemia on nilotinib

    Article • Leukemia Research Reports, January 2013, Elsevier

    Professor Eric DECONINCK

  127. French Multicenter 22-Year Experience in Stem Cell Transplantation for Beta-Thalassemia Major: Lessons and Future Directions

    Article • Biology of Blood and Marrow Transplantation, January 2013, Elsevier

    Professor Eric DECONINCK

  128. Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies

    Article • Journal of Clinical Oncology, December 2012, American Society of Clinical Oncology (ASCO)

    Professor Eric DECONINCK

  129. Treatment of adult ALL with central nervous system involvement at diagnosis using autologous and allogeneic transplantation: a study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire

    Article • British Journal of Pharmacology, November 2012, Springer Science + Business Media

    Professor Eric DECONINCK

  130. Watchful Waiting in Low–Tumor Burden Follicular Lymphoma in the Rituximab Era: Results of an F2-Study Database

    Article • Journal of Clinical Oncology, November 2012, American Society of Clinical Oncology (ASCO)

    Professor Eric DECONINCK

  131. A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients w...

    Article • Annals of Oncology, October 2012, Elsevier

    Professor Eric DECONINCK

  132. Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up

    Article • Annals of Oncology, September 2012, Elsevier

    Professor Eric DECONINCK

  133. Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma

    Article • Journal of Hematology & Oncology, June 2012, Springer Science + Business Media

    Professor Eric DECONINCK

  134. Intracytoplasmic detection of TCL1—but not ILT7—by flow cytometry is useful for blastic plasmacytoid dendritic cell leukemia diagnosis

    Article • Cytometry Part A, June 2012, Wiley

    Dr Philippe SAAS, Professor Eric DECONINCK

  135. High-Dose Therapy and Autologous Stem Cell Transplantation in First Relapse for Diffuse Large B Cell Lymphoma in the Rituximab Era: An Analysis Based on Data from the European Blood and Marrow Transplantation Registry

    Article • Biology of Blood and Marrow Transplantation, May 2012, Elsevier

    Professor Eric DECONINCK

  136. Double Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Study from the SFGM-TC

    Article • Biology of Blood and Marrow Transplantation, February 2012, Elsevier

    Professor Eric DECONINCK

  137. Systematic donor blood qualification by flow cytometry would have been able to avoid CLL‐type MBL transmission after unrelated hematopoietic stem cell transplantation

    Article • European Journal Of Haematology, January 2012, Wiley

    Professor Eric DECONINCK

  138. CD304 is preferentially expressed on a subset of B‐lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry

    Article • Cytometry Part A, November 2011, Wiley

    Dr Philippe SAAS, Professor Eric DECONINCK

  139. Successful mobilization and engraftment of PBSCs derived from donor cord blood cells after a previous allogeneic RIC single unrelated cord blood transplantation

    Article • Blood, July 2011, American Society of Hematology

    Dr Philippe SAAS, Professor Eric DECONINCK

  140. Long-Term Follow-Up of Tandem High-Dose Therapy with Autologous Stem Cell Support for Adults with High-Risk Age-Adjusted International Prognostic Index Aggressive non-Hodgkin Lymphomas: A GOELAMS Pilot Study

    Article • Biology of Blood and Marrow Transplantation, June 2011, Elsevier

    Professor Eric DECONINCK

  141. ERRATA

    Article • Transfusion, May 2011, Wiley

    Professor Eric DECONINCK

  142. Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study

    Article • Haematologica, April 2011, Ferrata Storti Foundation (Haematologica)

    Professor Eric DECONINCK

  143. Retrospective assessment of β‐d‐(1,3)‐glucan for presumptive diagnosis of fungal infections

    Article • Apmis, February 2011, Wiley

    Professor Eric DECONINCK

  144. Increased risk of non-Hodgkin lymphoma and serum organochlorine concentrations among neighbors of a municipal solid waste incinerator

    Article • Environment International, February 2011, Elsevier

    Professor Eric DECONINCK

  145. Intrathecal liposomal cytarabine (lipoCIT) administration in patients with leukemic or lymphomatous meningitis

    Article • Investigational New Drugs, January 2011, Springer Science + Business Media

    Professor Eric DECONINCK

  146. Ribosomal and Mitochondrial DNA Target for Real-Time PCR Diagnosis of Invasive Aspergillosis

    Article • Journal of Clinical Microbiology, January 2011, ASM Journals

    Professor Eric DECONINCK

  147. Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, December 2010, New England Journal of Medicine (NEJM/MMS)

    Professor Eric DECONINCK

  148. Persistence of lymphocyte function perturbations after granulocyte–colony‐stimulating factor mobilization and cytapheresis in normal peripheral blood stem cell donors

    Article • Transfusion, December 2010, Wiley

    Professor Eric DECONINCK

  149. Allogeneic Stem-Cell Transplantation in Patients With Waldenström Macroglobulinemia: Report From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

    Article • Journal of Clinical Oncology, November 2010, American Society of Clinical Oncology (ASCO)

    Professor Eric DECONINCK

  150. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology

    Article • Transfusion, October 2010, Wiley

    Professor Raymond Goodrich, Professor Eric DECONINCK

  151. Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission

    Article • Blood, October 2010, American Society of Hematology

    Professor Eric DECONINCK

  152. Computerized physician order entry of injectable antineoplastic drugs: An epidemiologic study of prescribing medication errors

    Article • International Journal of Medical Informatics, October 2010, Elsevier

    Professor Eric DECONINCK

  153. Upfront VIP‐reinforced‐ABVD (VIP‐rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS‐LTP95

    Article • British Journal of Haematology, August 2010, Wiley

    Professor Eric DECONINCK

  154. Diagnosis and treatment of digestive cryptosporidiosis in allogeneic haematopoietic stem cell transplant recipients: a prospective single centre study

    Article • British Journal of Pharmacology, August 2010, Springer Science + Business Media

    Professor Eric DECONINCK

  155. Early immune reconstitution and efficient graft vs tumor effect after unrelated partially matched double cord blood transplantation in refractory 8p11 syndrome

    Article • British Journal of Pharmacology, July 2010, Springer Science + Business Media

    Dr Philippe SAAS, Professor Eric DECONINCK

  156. False-positiveAspergillusreal-time PCR assay due to a nutritional supplement in a bone marrow transplant recipient with GVH disease

    Article • Medical Mycology, June 2010, Oxford University Press (OUP)

    Professor Eric DECONINCK

  157. Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance

    Article • Blood, March 2010, American Society of Hematology

    Professor Eric DECONINCK

  158. Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group

    Article • Haematologica, March 2010, Ferrata Storti Foundation (Haematologica)

    Professor Eric DECONINCK

  159. G-CSF–induced aneuploidy does not affect CD34+ cells and does not require cell division

    Article • Blood, January 2010, American Society of Hematology

    Professor Eric DECONINCK

  160. Cost Effectiveness of Rituximab Maintenance Therapy in Follicular Lymphoma

    Article • PharmacoEconomics, January 2010, Springer Science + Business Media

    Professor Eric DECONINCK

  161. Pharmacokinetic Modelling and Development of Bayesian Estimators for Therapeutic Drug Monitoring of Mycophenolate Mofetil in Reduced-Intensity Haematopoietic Stem Cell Transplantation

    Article • Clinical Pharmacokinetics, October 2009, Springer Science + Business Media

    Professor Eric DECONINCK

  162. Pharmacokinetics of Mycophenolic Acid Administered 3 Times Daily after Hematopoietic Stem Cell Transplantation with Reduced-Intensity Regimen

    Article • Biology of Blood and Marrow Transplantation, September 2009, Elsevier

    Professor Eric DECONINCK

  163. Infliximab Treatment for Steroid-Refractory Acute Graft-Versus-Host Disease After Orthotopic Liver Transplantation: A Case Report

    Article • Liver Transplantation, July 2009, Wolters Kluwer Health

    Professor Eric DECONINCK

  164. Improved Outcome of Acute Promyelocytic Leukemia With High WBC Counts Over the Last 15 Years: The European APL Group Experience

    Article • Journal of Clinical Oncology, June 2009, American Society of Clinical Oncology (ASCO)

    Professor Eric DECONINCK

  165. Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia

    Article • British Journal of Haematology, May 2009, Wiley

    Dr Philippe SAAS, Professor Eric DECONINCK

  166. Evidence for anti-tumour effect of allogeneic haematopoietic SCT in cases without sustained donor engraftment

    Article • British Journal of Pharmacology, May 2009, Springer Science + Business Media

    Professor Eric DECONINCK

  167. Conservation et indications des greffons de sang placentaire

    Article • Transfusion Clinique et Biologique, May 2009, Elsevier

    Professor Eric DECONINCK

  168. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation

    Article • Haematologica, April 2009, Ferrata Storti Foundation (Haematologica)

    Professor Eric DECONINCK

  169. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 y...

    Article • Blood, January 2009, American Society of Hematology

    Professor Eric DECONINCK

  170. Cost Effectiveness of High-Dose Chemotherapy with Autologous Stem Cell Support as Initial Treatment of Aggressive Non-Hodgkinʼs Lymphoma

    Article • PharmacoEconomics, January 2009, Springer Science + Business Media

    Professor Eric DECONINCK

  171. Maladie de Randall, simulant une maladie de Gougerot-Sjögren, traitée avec succès par chimiothérapie et autogreffe de moelle osseuse

    Article • La Revue de Médecine Interne, January 2009, Elsevier

    Professor Eric DECONINCK

  172. Allogeneic Hematopoietic Stem-Cell Transplantation for Myeloid Sarcoma: A Retrospective Study From the SFGM-TC

    Article • Journal of Clinical Oncology, October 2008, American Society of Clinical Oncology (ASCO)

    Professor Eric DECONINCK

  173. Early Immune Response Against Retrovirally Transduced Herpes Simplex Virus Thymidine Kinase-Expressing Gene-Modified T Cells Coinfused with a T Cell-Depleted Marrow Graft: An Altered Immune Response?

    Article • Human Gene Therapy, September 2008, SAGE Publications

    Professor Eric DECONINCK

  174. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials

    Article • Blood, May 2008, American Society of Hematology

    Professor Eric DECONINCK

  175. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire

    Article • Experimental Hematology, May 2008, Elsevier

    Professor Eric DECONINCK

  176. Deletions within the HSV-tk transgene in long-lasting circulating gene-modified T cells infused with a hematopoietic graft

    Article • Blood, December 2007, American Society of Hematology

    Professor Eric DECONINCK

  177. Occurrence and severity of adverse events after autologous hematopoietic progenitor cell infusion are related to the amount of granulocytes in the apheresis product

    Article • Transfusion, May 2007, Wiley

    Professor Eric DECONINCK

  178. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC)

    Article • Haematologica, May 2007, Ferrata Storti Foundation (Haematologica)

    Professor Eric DECONINCK

  179. Is Cytarabine Useful in the Treatment of Acute Promyelocytic Leukemia? Results of a Randomized Trial From the European Acute Promyelocytic Leukemia Group

    Article • Journal of Clinical Oncology, December 2006, American Society of Clinical Oncology (ASCO)

    Professor Eric DECONINCK

  180. Quantification de Stachybotrys chartarum par PCR en temps réel dans l'environnement domestique, hospitalier, et agricole

    Article • Journal de Mycologie Médicale, December 2006, Elsevier

    Professor Eric DECONINCK

  181. Leucémies aiguës chez deux patients atteints de sclérose en plaques et traités par mitoxantrone

    Article • Revue Neurologique, February 2006, Elsevier

    Professor Eric DECONINCK

  182. Conversion from Mycophenolate Mofetil to Enteric-coated Mycophenolate Sodium (myfortic??) Resolves Gastrointestinal Disorders in a Patient with Severe Idiopathic Aplastic Anaemia

    Article • Drugs, January 2006, Springer Science + Business Media

    Professor Eric DECONINCK

  183. Use of Real-Time PCR To Process the First Galactomannan-Positive Serum Sample in Diagnosing Invasive Aspergillosis

    Article • Journal of Clinical Microbiology, October 2005, ASM Journals

    Professor Eric DECONINCK

  184. Intensive Therapy before or during the Conditioning Regimen of Allogeneic Marrow Transplantation in Adult Acute Lymphoblastic Leukemia Patients: We Must Choose to Reduce Toxicity—A Groupe Ouest-Est d’Etude des Leucémies et Autres Maladies du Sang Study

    Article • Biology of Blood and Marrow Transplantation, June 2005, Elsevier

    Professor Eric DECONINCK

  185. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS

    Article • Blood, May 2005, American Society of Hematology

    Professor Eric DECONINCK

  186. Peripheral T-cell expansion and low infection rate after reduced-intensity conditioning and allogeneic blood stem cell transplantation

    Article • British Journal of Pharmacology, March 2005, Springer Science + Business Media

    Dr Philippe SAAS, Professor Eric DECONINCK

  187. Long-term follow-up of a randomized trial of fludarabine–mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era...

    Article • Annals of Oncology, March 2005, Elsevier

    Professor Eric DECONINCK

  188. c‐Flip protein expression in Burkitt's lymphomas is associated with a poor clinical outcome

    Article • British Journal of Haematology, March 2005, Wiley

    Professor Eric DECONINCK

  189. The efficiency of transfusing high doses of platelets in hematologic patients with thrombocytopenia: results of a prospective, randomized, open, blinded end point (PROBE) study

    Article • Blood, January 2005, American Society of Hematology

    Professor Eric DECONINCK

  190. Cost Effectiveness of Cardioprotective Strategies in Patients with Aggressive Non-Hodgkin???s Lymphoma

    Article • Clinical Drug Investigation, January 2005, Springer Science + Business Media

    Professor Eric DECONINCK

  191. Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells

    Article • Blood, September 2004, American Society of Hematology

    Dr Philippe SAAS, Professor Eric DECONINCK

  192. Efficacy and Safety of Oral Fludarabine Phosphate in Previously Untreated Patients With Chronic Lymphocytic Leukemia

    Article • Journal of Clinical Oncology, April 2004, American Society of Clinical Oncology (ASCO)

    Professor Eric DECONINCK

  193. Initial Treatment of Aggressive Lymphoma with High-Dose Chemotherapy and Autologous Stem-Cell Support

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, March 2004, New England Journal of Medicine (NEJM/MMS)

    Professor Eric DECONINCK

  194. Renal toxicity after bone marrow transplantation

    Article • International Journal of Radiation Oncology*Biology*Physics, March 2004, Elsevier

    Professor Eric DECONINCK

  195. Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome

    Article • British Journal of Pharmacology, January 2004, Springer Science + Business Media

    Professor Eric DECONINCK

  196. A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes

    Article • The Hematology Journal, January 2004, Springer Science + Business Media

    Professor Eric DECONINCK

  197. Hepatosplenic    T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients

    Article • Blood, December 2003, American Society of Hematology

    Professor Eric DECONINCK

  198. A Single Intravenous Infusion of Apoptotic Cells, An Alternative Cell-Based Therapy Approach Facilitating Hematopoietic Cell Engraftment, Did Not Induce Autoimmunity

    Article • Journal of Hematotherapy & Stem Cell Research, August 2003, Mary Ann Liebert Inc

    Dr Philippe SAAS, Professor Eric DECONINCK

  199. A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society

    Article • British Journal of Pharmacology, May 2003, Springer Science + Business Media

    Professor Eric DECONINCK

  200. Early cardiotoxicity of the CHOP regimen in aggressivenon-Hodgkin’s lymphoma

    Article • Annals of Oncology, February 2003, Elsevier

    Professor Eric DECONINCK

  201. Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial

    Article • Leukemia, February 2003, Springer Science + Business Media

    Professor Eric DECONINCK

  202. Erratum: J Neurol (2002) 249:1482

    Article • Deutsche Zeitschrift für Nervenheilkunde, November 2002, Springer Science + Business Media

    Professor Eric DECONINCK

  203. Erratum: J Neurol (2002) 249: 1088-1097

    Article • Deutsche Zeitschrift für Nervenheilkunde, October 2002, Springer Science + Business Media

    Professor Eric DECONINCK

  204. Factor XIII replacement in stem-cell transplant recipients with severe hemorrhagic cystitis: a report of four cases

    Article • Transplantation, October 2002, Wolters Kluwer Health

    Professor Eric DECONINCK

  205. Hematopoietic stem cell transplantation for multiple sclerosis

    Article • Deutsche Zeitschrift für Nervenheilkunde, July 2002, Springer Science + Business Media

    Professor Eric DECONINCK

  206. Polyvisceral arteritis in chronic graft-versus-host disease: antiphospholipid-negative thrombotic syndrome mimicking polyarteritis nodosa

    Article • British Journal of Pharmacology, May 2002, Springer Science + Business Media

    Professor Eric DECONINCK

  207. Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin–cyclin B link

    Article • Leukemia, April 2002, Springer Science + Business Media

    Professor Eric DECONINCK

  208. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease

    Article • Blood, November 2001, American Society of Hematology

    Professor Eric DECONINCK

  209. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft

    Article • Blood, January 2001, American Society of Hematology

    Dr Philippe SAAS, Professor Eric DECONINCK

  210. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation

    Article • Blood, January 2001, American Society of Hematology

    Professor Eric DECONINCK

  211. Effect of cell determinant (CD)34+ cell dose on the cost and consequences of peripheral blood stem cell transplantation for non-Hodgkin's lymphoma patients in front-line therapy

    Article • European Journal of Cancer, December 2000, Elsevier

    Professor Eric DECONINCK

  212. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial

    Article • British Journal of Haematology, December 2000, Wiley

    Professor Eric DECONINCK

  213. Toxoplasmosis after Hematopoietic Stem Cell Transplantation

    Article • Clinical Infectious Diseases, November 2000, Oxford University Press (OUP)

    Professor Eric DECONINCK

  214. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study

    Article • British Journal of Pharmacology, November 2000, Springer Science + Business Media

    Professor Eric DECONINCK

  215. Autologous stem cell transplantation for anaplastic large‐cell lymphomas: results of a prospective trial

    Article • British Journal of Haematology, June 2000, Wiley

    Professor Eric DECONINCK

  216. Toxoplasmosis after hematopoietic stem transplantation. Report of a 5-year survey from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

    Article • British Journal of Pharmacology, May 2000, Springer Science + Business Media

    Professor Eric DECONINCK

  217. Cost-effectiveness of CD34+ dose in peripheral blood progenitor cell transplantation for non-Hodgkin’s lymphoma patients: a single centre study

    Article • British Journal of Pharmacology, April 2000, Springer Science + Business Media

    Professor Eric DECONINCK

  218. Allogeneic Bone Marrow Transplantation for Therapy-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Long-Term Study of 70 Patients—Report of the French Society of Bone Marrow Transplantation

    Article • Journal of Clinical Oncology, March 2000, American Society of Clinical Oncology (ASCO)

    Professor Eric DECONINCK

  219. Granulocyte Colony-Stimulating Factor After Intensive Consolidation Chemotherapy in Acute Myeloid Leukemia: Results of a Randomized Trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques

    Article • Journal of Clinical Oncology, February 2000, American Society of Clinical Oncology (ASCO)

    Professor Eric DECONINCK

  220. A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia

    Article • Blood, August 1999, American Society of Hematology

    Professor Eric DECONINCK

  221. Low dose T-cell lymphocyte infusion combined with marrow T-cell depletion as prophylaxis of acute graft vs host disease for HLA identical sibling bone marrow transplantation

    Article • Hematology and Cell Therapy, April 1999, Springer Science + Business Media

    Professor Eric DECONINCK

  222. Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Coopératif Macroglobulinémie.

    Article • Journal of Clinical Oncology, June 1998, American Society of Clinical Oncology (ASCO)

    Professor Eric DECONINCK

  223. Prolonged remission and autologous recovery in two patients with chronic myelogenous leukemia after graft failure of allogeneic bone marrow transplantation

    Article • British Journal of Pharmacology, April 1998, Springer Science + Business Media

    Professor Eric DECONINCK

  224. Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas

    Article • Leukemia, February 1998, Springer Science + Business Media

    Professor Eric DECONINCK

  225. High-dose therapy followed by stem cell transplantation in partial response after first-line induction therapy for aggressive non-Hodgkin’s lymphoma

    Article • Annals of Oncology, January 1998, Elsevier

    Professor Eric DECONINCK

  226. Cost comparative study of autologous peripheral blood progenitor cells (PBPC) and bone marrow (ABM) transplantations for non-Hodgkin’s lymphoma patients

    Article • British Journal of Pharmacology, December 1997, Springer Science + Business Media

    Professor Eric DECONINCK

  227. Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia in first remission: long-term results for 42 patients conditioned with an intensified regimen (TBI, high-dose Ara-C and melphalan)

    Article • British Journal of Pharmacology, November 1997, Springer Science + Business Media

    Professor Eric DECONINCK

  228. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years.

    Article • Journal of Clinical Oncology, August 1997, American Society of Clinical Oncology (ASCO)

    Professor Eric DECONINCK

  229. Use of Donor T-Lymphocytes Expressing Herpes-Simplex Thymidine Kinase in Allogeneic Bone Marrow Transplantation: A Phase I–II Study. Laboratorie d'Histocompatibilité et Thérapeutique Immuno-Moléculaire, Besançon, France

    Article • Human Gene Therapy, March 1997, SAGE Publications

    Professor Eric DECONINCK

  230. Article • Annals of Oncology, January 1997, Elsevier

    Professor Eric DECONINCK

  231. Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage 111-IV patients

    Article • Annals of Oncology, January 1997, Elsevier

    Professor Eric DECONINCK

  232. Placebo-Controlled phase III Study of lenograstim (Glycosylated recombinant human granulocyte colony-Stimulating factor) in Aggressive non-Hodgkin's lymphoma: Factors influencing chemotherapy administration

    Article • Leukemia & Lymphoma, January 1997, Taylor & Francis

    Professor Eric DECONINCK

  233. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group

    Article • Blood, October 1996, American Society of Hematology

    Professor Eric DECONINCK

  234. High-dose dexamethasone therapy for resistant autoimmune thrombocytopenic purpura

    Article • American Journal of Hematology, April 1996, Wiley

    Professor Eric DECONINCK

  235. PHOTOTHERAPY IN THE TREATMENT OF CUTANEOUS GRAFT-VERSUS-HOST DISEASE

    Article • Transplantation, January 1995, Wolters Kluwer Health

    Professor Eric DECONINCK

  236. Translocation chromosomique t (14, 18) et lymphomes non hodgkiniens: résultats préliminaires à propos de 30 lymphomes folliculaires analysés par PCR

    Article • La Revue de Médecine Interne, June 1993, Elsevier

    Professor Eric DECONINCK

  237. Graft Failure after T Cell Depleted HLA Identical Allogeneic Bone Marrow Transplantation: Risk Factors in Leukemic Patients

    Article • Leukemia & Lymphoma, January 1993, Taylor & Francis

    Professor Eric DECONINCK

  238. Prevention of veno-occlusive disease of the liver after bone marrow transplantation: heparin or no heparin? [letter; comment]

    Article • Blood, October 1992, American Society of Hematology

    Professor Eric DECONINCK

  239. Aplasie post-chimiothérapie et autogreffe de moëlle osseuse: apport des facteurs de croissance hématopoïétiques

    Article • La Revue de Médecine Interne, November 1991, Elsevier

    Professor Eric DECONINCK

  240. Biologie et applications cliniques des principales cytokines hématopoïétiques (GM-CSF, G-CSF, IL-3, IL-6, IL-1)

    Article • Revue Française de Transfusion et d Hémobiologie, July 1990, Elsevier

    Professor Eric DECONINCK